Impact of vaccine effectiveness and coverage on preventing large mumps outbreaks on college campuses: Implications for vaccination strategy.

Epidemics

Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.

Published: September 2022

AI Article Synopsis

  • Recent mumps outbreaks in vaccinated college populations have raised concerns about the effectiveness of the two-dose MMR vaccine, prompting a study to determine the required vaccine effectiveness (VE) for a new vaccination strategy to prevent these outbreaks.
  • The study analyzed mumps outbreak data from 2016-2017 and estimated that the median VE of the MMR vaccine during these outbreaks was 60.5%, with a vaccination coverage (VC) of 97.5%.
  • To prevent significant outbreaks, maintaining a VC of 97.5% requires the new vaccination strategy to achieve a VE between 73.1% and 85.9%, especially among young adults on college campuses.

Article Abstract

Recent mumps outbreaks among highly vaccinated populations, including college students, have called into question the vaccine effectiveness (VE) of routine two-dose measles, mumps, and rubella (MMR2) immunization. We aimed to estimate the VE required for a novel vaccination strategy (e.g., MMR booster dose, novel vaccine) to prevent large mumps outbreaks on college campuses. Using mumps college outbreak data reported to the U.S. Centers for Disease Control and Prevention during 2016-2017, we estimated current MMR2 VE using the screening method and implemented a compartmental model of mumps transmission. We performed 2000 outbreak simulations, following introduction of an infectious person to a population of 10,000, over ranges of MMR2 vaccine coverage (VC) and VE (30.0-99.0%). We compared the impact of varying VC and VE on mumps and mumps orchitis case counts and determined VE thresholds that ensured < 5.0% and < 2.0% of the outbreak simulations exceeded 20 and 100 mumps cases. Median estimated MMR2 VE in reported mumps outbreaks was 60.5% and median reported MMR2 VC was 97.5%. Simulated mumps case count was more sensitive to changes in VE than in VC. The opposite was true for simulated mumps orchitis case count, though orchitis case count was small (mean <10 cases across simulations for VE near 60.5% and VC near 97.5%). At 97.5% VC, 73.1% and 78.2% VE were required for < 5.0% and < 2.0% of outbreaks, respectively, to exceed 100 mumps cases. Maintaining 97.5% VC, 82.4% and 85.9% VE were required for < 5.0% and < 2.0% of outbreaks, respectively, to exceed 20 cases. We conclude that maintaining current levels of MMR2 VC, a novel vaccination strategy aimed at reducing mumps transmission must achieve at least 73.1-85.9% VE among young adults to prevent large mumps outbreaks on college campuses.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.epidem.2022.100594DOI Listing

Publication Analysis

Top Keywords

mumps outbreaks
12
vaccine effectiveness
8
mumps
8
large mumps
8
outbreaks college
8
college campuses
8
vaccination strategy
8
impact vaccine
4
effectiveness coverage
4
coverage preventing
4

Similar Publications

Vaccination against measles-mumps-rubella and rates of non-targeted infectious disease hospitalisations: Nationwide register-based cohort studies in Denmark, Finland, Norway, and Sweden.

J Infect

January 2025

Bandim Health Project, Research Unit OPEN, Department of Clinical Research, University of Southern Denmark, Odense C, Denmark; Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.

Objectives: To investigate if receipt of measles-mumps-rubella (MMR) vaccine following the third dose of diphtheria-tetanus-acellular pertussis (DTaP3) is associated with reduced rates of non-targeted infectious disease hospitalisations.

Methods: Register based cohort study following 1,397,027 children born in Denmark, Finland, Norway, and Sweden until 2 years of age. Rates of infectious disease hospitalisations with minimum one overnight stay according to time-varying vaccination status were compared using Cox proportional hazards regression analysis with age as the underlying timescale and including multiple covariates.

View Article and Find Full Text PDF

Progress of Measles and Rubella Surveillance in the Context of Measles Elimination in the WHO Eastern Mediterranean Region, 2019-2022.

Vaccines (Basel)

November 2024

Department of Immunization, Vaccines and Biologicals, World Health Organization, 1202 Geneva, Switzerland.

In 2015, the 62nd session of the Regional Committee [RC] of the Eastern Mediterranean Region [EMR] endorsed the Eastern Mediterranean Vaccine Action Plan 2016-2020 (EMVAP) that included postponement of the measles elimination target to before 2020. However, the EMR does not have a regional rubella control or elimination goal. We reviewed the progress of measles and rubella surveillance in context of measles elimination in the Eastern Mediterranean Region during 2019-2022.

View Article and Find Full Text PDF
Article Synopsis
  • Mumps is primarily a childhood infection characterized by swollen parotid glands, but a recent outbreak in Chile affected adults aged 20-35 despite the earlier success of the triple virus vaccine.
  • During 2018-2019, researchers analyzed 592 suspected mumps cases, finding a significant percentage positive for mumps antibodies (19.8% IgM and 95.9% IgG), with a notable male majority among positive IgM cases.
  • Genetic analysis revealed G and N genotypes in some cases, highlighting the importance of laboratory findings in diagnosing mumps and understanding the outbreak through an epidemiological surveillance program.
View Article and Find Full Text PDF

Objective: Children with Chronic Kidney Disease (CKD) are at increased risk for vaccine-preventable diseases. The primary objective of the study was to estimate IgG antibody titers against measles, mumps, and rubella (MMR) in children with CKD and healthy controls who were previously immunized with measles/ MMR vaccine.

Methods: This case control study was conducted between January 2019 and January 2020.

View Article and Find Full Text PDF

Introduction: Measles remains a public health concern, particularly among populations with suboptimal vaccination coverage, including immigrants. Understanding the seroprevalence of measles antibodies in immigrant populations is essential to inform tailored vaccination strategies and reduce the risk of measles reintroduction.

Methods: This study evaluated measles IgG seroprevalence among 651 immigrants from 30 countries residing in Gwangju, South Korea.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!